Fig. 6From: Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathwaysSyndecan-1 silencing attenuates the activation of STAT-3 and NFκB signaling pathways and downregulates protein expression of gp130 in SUM-149 and SKBR3 cells. Seventy-two hours post transfection total cell lysates of control and Syndecan-1 knockdown cells were collected, electrophoresed and immunoblotted. The membrane was probed with the indicated antibodies. a Western blot showing expression of p-STAT-3, STAT-3, p-NFκB, NFκB and gp130 upon Syndecan-1 silencing in SUM-149 and SKBR-3 cells. b Immunoblot band intensities were normalized to the total form of STAT-3, NFκB or tubulin expression. Data shown are a single experiment representative of three independent experiments. * P < 0.05, ** P < 0.01 and # P < 0.001 as determined by Student’s t-testBack to article page